查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735698

全球人类疫苗佐剂市场规模（按类型、给药途径、应用、区域范围）预测（至 2025 年）

Global Human Vaccine Adjuvants Market Size By Type, By Route Of Administration, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

人用疫苗佐剂的市场规模及预测

2024 年人类疫苗佐剂市场规模价值 15.9 亿美元，预计到 2032 年将达到 45 亿美元，预测期内（2026-2032 年）的复合年增长率为 12.1%。

推动全球人类疫苗佐剂市场的因素

人类疫苗佐剂市场的驱动因素可能受到多种因素的影响。这些因素包括：

  • 感染疾病爆发：感染疾病持续对世界各地的公共卫生构成严重威胁，增加了对疫苗的需求，这就是为什么需要佐剂来提高疫苗接种的有效性。
  • 疫苗研发投入增加：新冠疫情等疫情爆发后，各国政府、私人机构及製药公司纷纷增加对疫苗研发的投资。由于这些投资的增加，用于增强疫苗效力的佐剂的需求也随之增加。
  • 技术发展：免疫学和技术的突破带来了能够引发更强免疫反应的创新佐剂，增加了这些产品的市场需求。
  • 老年人口不断增加：随着老龄化增长，老年人的免疫功能下降，更容易感染疾病。因此，人们越来越重视开发针对带状疱疹、肺炎和流感等疾病的疫苗，并且需要针对老年人更有效的佐剂。
  • 扩大免疫接种计划：为了阻止感染疾病的传播，各国政府和国际组织正在实施广泛的免疫接种计划，尤其是在开发中国家。因此，需要疫苗佐剂来资助这些工作。
  • 提高公众对预防性医疗保健的认识：随着公众对疫苗接种在疾病预防中的价值的认识不断提高，公众对疫苗的接受度也在不断提高，从而对增强免疫反应和提高疫苗有效性的佐剂的需求也随之增加。
  • 加强大流行病防范：COVID-19 和最近的大流行凸显了防范新发感染疾病的重要性，导致对佐剂研究和疫苗开发的投资增加，以便能够快速应对未来可能爆发的感染疾病。
  • 监管支援：监管机构逐渐意识到佐剂在疫苗研发中的价值，并正在加快佐剂疫苗的核准流程，奖励製药公司投入资源进行佐剂的研发，有助于扩大市场。

限制全球人类疫苗佐剂市场的因素

人类疫苗佐剂市场面临诸多限制与挑战，包括：

  • 监管挑战：佐剂受到各国政府的严格审查，因为它们会影响疫苗的安全性和有效性。满足监管核准标准可能耗时耗力，成本高昂，这可能会阻碍新业务进入市场。
  • 安全问题：有安全问题的佐剂在疫苗製剂中可能较少使用。佐剂可能引起注射部位的不良反应或局部不适，这可能会阻碍患者和医护人员的接种。
  • 成本限制：佐剂的开发和生产成本可能很高，尤其是独特或专有配方。昂贵的疫苗生产成本可能高成本，这限制了某些患者群体和资源匮乏地区的疫苗供应。
  • 采用率有限：由于传统的非佐剂疫苗可能已在市场上广泛普及，新的佐剂疫苗可能难以广泛认可。除非有确凿证据显示新产品的安全性或有效性有所提高，否则病患和医护人员可能不愿意转向新产品。
  • 智慧财产权问题：添加剂技术的智慧财产权可能会使新竞争对手难以进入市场。专利纠纷、专有配方和授权协议可能会抑制市场竞争和创新。
  • 生产挑战：扩大佐剂疫苗的生产规模可能相当具有挑战性，需要特定的设施和生产技术。佐剂疫苗的供应和成本可能会受到生产限制（包括产能有限和生产延迟）的影响。
  • 公众舆论与采用：佐剂的采用和吸收可能会受到公众对佐剂的看法的影响，而公众对疫苗的犹豫、虚假资讯等因素则会影响佐剂的采用和吸收。透过教育和沟通倡议解决安全性和有效性问题对于佐剂市场的繁荣至关重要。
  • 全球健康差距：不同地区和社会经济群体在医疗保健和免疫接种方面的差异可能会加剧佐剂疫苗的市场限制。为了促进市场成长，必须透过集中定价、协调监管和增加基础设施支出来解决这些差距。

目录

第一章全球人类疫苗佐剂市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 人用疫苗佐剂的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球人类疫苗佐剂市场（按类型）

  • 概述
  • 铝盐
  • 油基佐剂
  • 无机盐
  • 佐剂系统

6. 全球人类疫苗佐剂市场（依应用）

  • 感染疾病疫苗
  • 癌症疫苗
  • 自体免疫疾病疫苗

7. 全球人用疫苗佐剂市场（依给药途径）

  • 肌肉注射（IM）
  • 皮下（SC）给药
  • 皮内（ID）给药

8. 全球人用疫苗佐剂市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
  • 拉丁美洲
  • 中东和非洲

9. 全球人类疫苗佐剂市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Serum Institute of India
  • Brenntag Biosector
  • CSL Limited
  • SEPPIC
  • Agenus, Inc.
  • Novavax, Inc.
  • SPI Pharma, Inc.
  • Invivogen
  • Avanti Polar Lipids
  • MVP Laboratories

第十一章 附录

  • 相关调查
简介目录
Product Code: 35939

Human Vaccine Adjuvants Market Size And Forecast

Human Vaccine Adjuvants Market size was valued at USD 1.59 Billion in 2024 and is projected to reach USD 4.5 Billion by 2032, growing at a CAGR of 12.1 % during the forecast period 2026-2032.

Global Human Vaccine Adjuvants Market Drivers

The market drivers for the Human Vaccine Adjuvants Market can be influenced by various factors. These may include:

  • Growing Prevalence of Infectious illnesses: Vaccine demand is rising as infectious illnesses continue to pose serious risks to public health around the world. This is the reason why adjuvants for vaccinations are necessary to increase their effectiveness.
  • Increasing Vaccine Development Investments: Following pandemics such as COVID-19, governments, private groups, and pharmaceutical firms are making significant investments in vaccine research and development. Adjuvants that can increase vaccine efficacy are in higher demand as a result of this increasing spending.
  • Technological Developments: Immunology and technological breakthroughs have produced innovative adjuvants that can elicit more robust immune responses, increasing the market's demand for these goods.
  • Growing Senior Population: As immune systems deteriorate with age, older people are more vulnerable to infectious diseases. Consequently, there is a growing emphasis on creating vaccinations against illnesses like shingles, pneumonia, and influenza, which need adjuvants to be more effective against older persons.
  • Extending immunization Programs: To stop the spread of infectious illnesses, particularly in developing nations, governments and international organizations are putting in place broad immunization programs. As a result, there is a need for vaccine adjuvants to fund these initiatives.
  • Growing Public Awareness of Preventive Healthcare: As public awareness of the value of vaccination in illness prevention rises, so does public acceptance of vaccines. Adjuvants that can boost immune responses and increase vaccine effectiveness are in high demand as a result.
  • Increase in Pandemic Preparedness: COVID-19 and other recent pandemics have brought attention to the significance of being ready for newly developing infectious illnesses. Investments in adjuvant research and vaccine development have increased as a result, enabling quick reactions to potential outbreaks in the future.
  • Regulatory Support: Regulatory bodies are expediting the approval procedures for adjuvanted vaccines as they become more aware of the value of adjuvants in vaccine development. This propels market expansion by incentivizing pharmaceutical companies to allocate resources on adjuvant research and development.

Global Human Vaccine Adjuvants Market Restraints

Several factors can act as restraints or challenges for the Human Vaccine Adjuvants Market. These may include:

  • Regulatory Difficulties: Because adjuvants may affect the safety and effectiveness of vaccines, they are closely inspected by the government. It might take time and money to comply with regulatory criteria for approval, which prevents new businesses from entering the market.
  • Safety Issues: Adjuvants that raise safety issues may not be used as much in vaccine formulations. Adjuvants have the potential to elicit negative reactions or localized discomfort at the injection site, which could make patients and healthcare providers hesitant.
  • Cost Restrictions: Adjuvant development and production can be expensive, especially for unique or proprietary formulas. Expensive vaccinations may be produced at high costs, which could restrict availability for some patient populations or in environments with limited resources.
  • Limited Adoption: It may be difficult for newly adjuvanted vaccinations to become widely accepted because traditional vaccines without adjuvants may already be well-established in the market. Patients and healthcare professionals could be hesitant to move to new products unless there is compelling proof of increased safety or efficacy.
  • Intellectual Property Problems: Adjunctive technology' intellectual property rights may make it difficult for new competitors to enter the market. Patent conflicts, proprietary formulae, and licensing agreements can stifle market competition and innovation.
  • Manufacturing Difficulties: Increasing the production of vaccines with adjuvants can be difficult and necessitate certain facilities and manufacturing techniques. Adjuvanted vaccine supply and cost may be impacted by manufacturing limitations such as capacity limitations or production delays.
  • Public opinion and adoption: Adjuvants' adoption and uptake can be impacted by the public's opinion of them, which can be shaped by things like vaccine hesitancy or disinformation. For the adjuvant market to flourish, it is imperative that safety and efficacy issues are addressed through education and communication initiatives.
  • Global Health Inequities: Market constraints for adjuvanted vaccines may be made worse by differences in the availability of healthcare and vaccinations among geographic or socioeconomic groups. For the market to grow, these disparities must be addressed by focused pricing tactics, harmonized regulations, and infrastructure spending.

Global Human Vaccine Adjuvants Market Segmentation Analysis

The Global Human Vaccine Adjuvants Market is Segmented on the basis of Type, Route of Administration, Application, and Geography.

Human Vaccine Adjuvants Market, By Type

  • Aluminum Salts: Traditional adjuvants widely used in vaccines to enhance immune response and improve antigen persistence. Examples include aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate.
  • Oil-based Adjuvants: Lipid-based formulations that promote antigen uptake and activation of immune cells. Examples include MF59 (squalene oil-in-water emulsion) and AS03 (squalene-based adjuvant system).
  • Mineral Salts: Adjuvants composed of mineral salts such as calcium phosphate, calcium carbonate, and magnesium hydroxide, which enhance antigen presentation and stimulate immune response.
  • Adjuvant Systems: Combination adjuvant formulations designed to elicit specific immune responses and enhance vaccine efficacy. Examples include AS04 (aluminum hydroxide with monophosphoryl lipid A) and AS01 (liposome-based adjuvant containing MPL and QS-21).

Human Vaccine Adjuvants Market, By Route of Administration

  • Intramuscular (IM) Administration: Vaccines administered via injection into the muscle, commonly utilizing adjuvants to enhance immunogenicity and promote long-lasting immunity.
  • Subcutaneous (SC) Administration: Vaccines injected under the skin, often incorporating adjuvants to improve antigen delivery and stimulate immune response.
  • Intradermal (ID) Administration: Vaccines administered directly into the skin using a microneedle or other delivery device, with adjuvants facilitating antigen uptake by immune cells in the dermis.

Human Vaccine Adjuvants Market, By Application

  • Infectious Diseases Vaccines: Adjuvants used in vaccines against infectious diseases such as influenza, hepatitis B, human papillomavirus (HPV), and meningococcal disease, aiming to induce protective immunity and prevent infection.
  • Cancer Vaccines: Adjuvants incorporated into cancer vaccines to stimulate immune responses against tumor-specific antigens, potentially leading to tumor regression or prevention of cancer recurrence.
  • Autoimmune Disease Vaccines: Adjuvants utilized in vaccines targeting autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus, aiming to modulate immune responses and induce tolerance to self-antigens.

Human Vaccine Adjuvants Market, By Geographic

  • North America: A significant market for human vaccine adjuvants, driven by high healthcare spending, extensive vaccination programs, and strong research and development activities in the pharmaceutical and biotechnology sectors.
  • Europe: Europe has a robust market for vaccine adjuvants, supported by the presence of leading vaccine manufacturers, government initiatives to promote immunization, and growing demand for novel adjuvant technologies.
  • Asia-Pacific: Emerging as a key market for human vaccine adjuvants, fueled by increasing awareness of preventive healthcare, rising incidence of infectious diseases, and expanding vaccine manufacturing capabilities in countries like China and India.
  • Latin America, Middle East, and Africa: These regions are witnessing growing investments in healthcare infrastructure, vaccination campaigns, and disease prevention efforts, driving demand for human vaccine adjuvants to improve vaccine efficacy and public health outcomes.

Key Players

  • The major players in the Human Vaccine Adjuvants Market are:
  • GlaxoSmithKline plc
  • Merck & Co Inc.
  • Novartis AG
  • AstraZeneca plc
  • Bavarian Nordic
  • Adjuvance Technologies Inc.
  • Vaxine Pty Ltd.
  • Dynavax Technologies Corporation

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMAN VACCINE ADJUVANTS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HUMAN VACCINE ADJUVANTS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Aluminum Salts
  • 5.3 Oil-based Adjuvants
  • 5.4 Mineral Salts
  • 5.5 Adjuvant Systems

6 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 6.1 Infectious Diseases Vaccines
  • 6.2 Cancer Vaccines
  • 6.3 Autoimmune Disease Vaccines

7 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1 Intramuscular (IM) Administration
  • 7.2 Subcutaneous (SC) Administration
  • 7.3 Intradermal (ID) Administration

8 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
  • 8.6 Latin America
  • 8.7 Middle East and Africa

9 GLOBAL HUMAN VACCINE ADJUVANTS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Serum Institute of India
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Brenntag Biosector
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 CSL Limited
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 SEPPIC
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Agenus, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Novavax, Inc.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 SPI Pharma, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Invivogen
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Avanti Polar Lipids
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 MVP Laboratories
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research